Vaccine sales help Crucell cut Q2 loss
An increase in the sale of vaccines such as Quinvaxem and Epaxal, helped Dutch drugmaker Crucell reduce its loss some 56 per cent to €7.9m ($12.5m) in the second quarter.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs